ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Launched by KIRBY INSTITUTE · Sep 24, 2018
Trial Information
Current as of June 25, 2025
Recruiting
Keywords
ClinConnect Summary
The ETHOS ENGAGE trial is focused on improving the care for people living with hepatitis C, particularly those who are using or have used drugs. The goal is to make it easier for individuals in drug treatment clinics and needle exchange programs to get tested and treated for hepatitis C in New South Wales, Australia. This trial is currently recruiting participants aged 18 and older who have a history of injecting drug use, including those who have used drugs recently or are receiving treatment to help them stop using drugs.
If you join the trial, you will have the opportunity to receive support and access to hepatitis C testing and treatment in a comfortable and understanding environment. Your participation will help researchers understand how to better provide these services in drug treatment settings, which could benefit many people in the future. Importantly, there are no specific medical conditions that would exclude you from joining, as long as you meet the age and drug use criteria. This is a chance to be part of an important effort to improve healthcare for individuals affected by hepatitis C.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participant has voluntarily signed the informed consent form;
- • 18 years of age or older;
- • History of injecting drug use\*;
- • Recent injecting drug use (previous six months) or currently receiving OST\*.
- • These criteria will not apply for recruitment from residential rehabilitation centres
- Exclusion Criteria:
- • Nil
About Kirby Institute
The Kirby Institute is a leading research organization based at the University of New South Wales (UNSW) in Australia, dedicated to advancing global health through innovative clinical research, particularly in the fields of infectious diseases, HIV, and public health. With a strong emphasis on collaboration, the Institute conducts rigorous clinical trials and epidemiological studies, translating scientific findings into effective health policies and practices. Its multidisciplinary team of researchers, clinicians, and public health experts works to improve health outcomes and inform treatment strategies, making significant contributions to both local and international health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Campbelltown, New South Wales, Australia
Darlinghurst, New South Wales, Australia
Liverpool, New South Wales, Australia
Mount Druitt, New South Wales, Australia
Nowra, New South Wales, Australia
Wollongong, New South Wales, Australia
Brisbane, Queensland, Australia
Cairns, Queensland, Australia
Brookvale, New South Wales, Australia
Cessnock, New South Wales, Australia
Coffs Harbour, New South Wales, Australia
Grafton, New South Wales, Australia
Katoomba, New South Wales, Australia
Kempsey, New South Wales, Australia
Kingswood, New South Wales, Australia
Lismore, New South Wales, Australia
Lithgow, New South Wales, Australia
Newcastle, New South Wales, Australia
Parramatta, New South Wales, Australia
Port Macquarie, New South Wales, Australia
Saint Leonards, New South Wales, Australia
Tamworth, New South Wales, Australia
Taree, New South Wales, Australia
Tweed Heads, New South Wales, Australia
Elizabeth, South Australia, Australia
Stepney, South Australia, Australia
Fremantle, Western Australia, Australia
Joondalup, Western Australia, Australia
Perth, Western Australia, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials